CARB-X FUNDS DEBIOPHARM

  15 May 2019

CARB-X is awarding Debiopharm International SA of Lausanne, Switzerland, up to $2.1 million in non-dilutive funding with the possibility of $1.6 million more if certain project milestones are met, to advance the development of a new class of antibiotics that inhibit bacterial fatty acid biosynthesis, an essential pathway in many drug-resistant bacterial species.  This new class of antibiotics is in development for the treatment of hospital-acquired pneumonia caused by the multidrug-resistant superbug Acinetobacter baumannii.

Source: CARB-X
Smart innovation  
Back


Advancing data technologies to corner AMR 2019

International Matchmaking Symposium on 5 June, 2019 in Amsterdam, The Netherlands.

Artificial Intelligence, Internet-of-Things and Blockchain to stop ever-escalating Antimicrobial resistance.

More information
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!